Pre‑Exposure Prophylaxis (PrEP) for HIV: Eligibility, Benefits, and Access Guidelines

1. Overview

Pre‑Exposure Prophylaxis, commonly abbreviated as PrEP, is a biomedical HIV‑prevention strategy that involves taking a daily oral medication to significantly reduce the risk of acquiring HIV infection. The most widely used regimen in the United States and many other countries combines two antiretroviral agents—tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)—sold under the brand name Truvada® or, more recently, a single‑tablet formulation containing tenofovir alafenamide (TAF) and FTC (brand name Descovy®). When taken consistently, clinical trials and real‑world studies have demonstrated a risk‑reduction of up to 99 % among individuals with high adherence.

PrEP is recommended for adults and adolescents who are HIV‑negative but have ongoing risk factors for HIV acquisition. It is an essential component of comprehensive sexual and reproductive health care, complementing other preventive measures such as condom use, regular HIV testing, and treatment as prevention (TasP) for people living with HIV.

2. Causes & Risk Factors

HIV infection occurs when the virus enters the bloodstream through mucosal surfaces or damaged skin. The probability of transmission varies by exposure type, viral load of the source partner, and presence of co‑existing sexually transmitted infections (STIs). PrEP is indicated for individuals whose behaviors place them at increased risk, including:

• Sexual exposure:
  • Men who have sex with men (MSM) who have condomless anal intercourse.
  • Heterosexual men and women who have condomless vaginal or anal intercourse with partners of unknown HIV status or known HIV‑positive status who are not virally suppressed.
  • Individuals with multiple concurrent sexual partners.
• Injection drug use:
  • People who inject drugs (PWID) and share needles or other injection equipment.
• Other clinical factors:
  • Recent diagnosis of an STI (e.g., chlamydia, gonorrhea, syphilis) which can increase susceptibility.
  • Sex work or transactional sex.
  • History of post‑exposure prophylaxis (PEP) use, indicating ongoing risk.

Guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) emphasize that eligibility should be based on a comprehensive risk assessment rather than a single behavior.

3. Signs & Symptoms

Because PrEP is a preventive medication, it does not treat active HIV infection and therefore does not produce symptoms of HIV. However, clinicians monitor for potential side effects and laboratory changes that may arise during PrEP use. Commonly reported, generally mild, adverse effects include:

• Gastrointestinal upset (nausea, abdominal discomfort) – usually transient.
• Headache.
• Fatigue.

Rare but clinically significant concerns include renal toxicity and reductions in bone mineral density, particularly with TDF‑based formulations. Routine laboratory monitoring (serum creatinine, estimated glomerular filtration rate, and, when appropriate, bone health assessments) is recommended at baseline, 3 months after initiation, and annually thereafter.

4. Prevention

• Consistent daily dosing: Adherence is the most critical determinant of efficacy. Studies show that taking ≥4 doses per week provides >90 % protection for MSM and >80 % for heterosexual women.
• Combined prevention strategies: PrEP should be used alongside condoms, regular STI screening, and vaccination (e.g., hepatitis B).
• Regular HIV testing: Baseline testing and follow‑up testing every 3 months confirm continued HIV‑negative status, which is required to remain on PrEP.
• Renal and bone health monitoring: Baseline labs and periodic re‑evaluation help identify early signs of toxicity.
• Risk‑reduction counseling: Healthcare providers should discuss substance use, sexual practices, and partner communication to support informed decision‑making.
• Access to affordable medication: Many insurance plans cover PrEP; patient assistance programs are available for uninsured or underinsured individuals.

5. Screening & Diagnosis

Before initiating PrEP, a thorough evaluation is required to ensure safety and appropriateness:

1. HIV testing: A fourth‑generation antigen/antibody assay is recommended to rule out acute infection. If the result is positive, PrEP is contraindicated and the individual should be linked to HIV care.
2. Renal function assessment: Serum creatinine and estimated glomerular filtration rate (eGFR) are measured. TDF‑based PrEP is generally not recommended for eGFR <60 mL/min/1.73 m².
3. Hepatitis B screening: Because TDF/FTC also treat hepatitis B virus (HBV), individuals with chronic HBV should be monitored closely; abrupt discontinuation can cause HBV flare.
4. STI testing: Gonorrhea, chlamydia, syphilis, and, when indicated, hepatitis C screening are performed at baseline and every 6–12 months.
5. Pregnancy testing: For women of child‑bearing potential, a urine or serum pregnancy test is required before starting PrEP. PrEP is considered safe in pregnancy, but counseling is essential.
6. Risk assessment interview: A non‑judgmental discussion of sexual practices, injection drug use, and other exposures guides eligibility decisions.

6. Treatment Options

Two FDA‑approved oral regimens are currently available for PrEP in the United States:

Both formulations are taken once daily. In certain circumstances, intermittent (event‑driven) dosing—known as “2‑1‑1” dosing—has been studied for MSM and shown to be effective when taken before and after sexual exposure. Event‑driven dosing is not recommended for cisgender women, transgender women, or PWID because pharmacokinetic data are insufficient.

For individuals who cannot tolerate oral PrEP or who have contraindications, long‑acting injectable cabotegravir (Apretude®) was approved by the FDA in 2022 for HIV prevention. The regimen consists of a 600 mg intramuscular injection every 8 weeks after an initial loading phase. Clinical trials (HPTN 083 and HPTN 084) demonstrated superior efficacy compared with daily oral TDF/FTC in both MSM and cisgender women.

7. Myths vs Facts

8. When to See a Doctor

Individuals should seek medical evaluation in the following circumstances:

• Before starting PrEP to confirm HIV‑negative status and assess kidney, liver, and bone health.
• Every 3 months for repeat HIV testing, STI screening, and adherence counseling.
• If symptoms suggest possible acute HIV infection (fever, rash, sore throat, lymphadenopathy) despite being on PrEP.
• When experiencing side effects that persist beyond the first few weeks, especially renal symptoms (e.g., decreased urine output) or bone pain.
• During pregnancy or planning pregnancy, to discuss continued PrEP use and fetal safety.
• If planning to stop PrEP, to arrange appropriate follow‑up testing and discuss alternative prevention strategies.

Conclusion

Pre‑Exposure Prophylaxis represents a cornerstone of modern HIV prevention, offering a highly effective biomedical tool for individuals at increased risk. Eligibility is determined through a personalized risk assessment, and the benefits—substantial reduction in HIV acquisition, empowerment of sexual health decision‑making, and integration into broader preventive care—are well documented. Access barriers continue to exist, but a combination of insurance coverage, patient assistance programs, and emerging long‑acting formulations are expanding availability.

Clinicians play a pivotal role in counseling, prescribing, and monitoring PrEP, ensuring that patients receive comprehensive education, routine laboratory surveillance, and support for adherence. By combining PrEP with established prevention methods such as condom use, regular STI testing, and treatment as prevention, the public health community moves closer to the goal of ending the HIV epidemic.